THE MAIN RESULTS OF COOPERATION BETWEEN THE V.A. NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY AND RESEARCH CENTERS OF EUROPE WITHIN THE EUSTAR (EULAR SCLERODERMA TRIALS AND RESEARCH GROUP) IN SYSTEMIC SCLEROSIS

The major goals of the EUSTAR (EULAR Scleroderma Trials And Research group) are to coordinate and centralize systemic sclerosis (SS) researches in Europe, to reach a consensus in the standards of evidence-based medicine for patient management, to enhance treatment efficacy, and to improve quality of life in patients and prognosis. Under the aegis of the EUSTAR, more than 100 centers have combined their efforts to solve basic research problems, to study the clinical aspects of the disease, and to conduct clinical trials. The major task of their activities has been to follow-up and timely treat SS patients examined according to a standard protocol, and to accumulate information in the unified European database that includes more than 10,000 patients now. The V.A. Nasonova Research Institute of Rheumatology has formed a cohort of 220 patients with SS, of whom 90–100 persons are annually followed up.
The main joint projects implemented have shown the present-day course of SS, studied the causes of death, and characteristics of patient subgroups (juvenile scleroderma, SS in the elderly, damage of the lung, heart, gastrointestinal tract, etc.). New diagnostic criteria for SS and an algorithm for its very early, preclinical diagnosis have been proposed. An analysis of the first 3656 patents with SS has revealed the major clinical characteristics of its diffuse and limited forms at the present stage. Pooled patient data have been used in international multicenter projects whose results are given in joint publications. The results of EUSTAR projects with the participation of the V.A. Nasonova Research Institute of Rheumatology are covered in 28 articles. Analysis of the results of EULAR/EUSTAR researches gives grounds to hold that the early diagnosis and timely detection of visceral injuries and the use of current therapy standards may assist in improving the quality of life of patients as well as in reducing the severity of SS and its mortality rates.

1. Tyndall A, Mueller-Ladner U, Matucci-Cerinic M. Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group database. Ann Rheum Dis. 2005;64(7):1107. DOI: http://dx.doi.org/10.1136/ard.2005.036038 Институт ревматологии указан в списке участников работы.

2. Meier FM, Frommer KW, Dinser R, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Collaborators. Ann Rheum Dis. 2012;71(8):1355–60. DOI: http://dx.doi.org/10.1136/annrheumdis-2011-200742. Институт ревматологии указан в списке участников работы.

3. Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis. 2011;70(3):476–81. DOI: http://dx.doi.org/10.1136/ard.2010.136929. Институт ревматологии указан в списке участников работы.

4. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66(6):754–63. DOI: http://dx.doi.org/10.1136/ard.2006.062901. Институт ревматологии указан в списке участников работы.

5. Avouac J, Kowal-Bielecka O, Landewe RB, et al. EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis. 2009;68(5):629–34. DOI: http://dx.doi.org/10.1136/ard.2008.095299. Институт ревматологии указан в списке участников работы.

6. Tyndall AJ, Bannert B, Vonk M, et al. (в соавт. Л.П. Ананьева). Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809-15. DOI: http://dx.doi.org/10.1136/ard.2009.114264.

7. Hü gle T, Schuetz P, Daikeler T, et al. Late-onset systemic sclerosis – a systematic survey of the EULAR scleroderma trials and research group database. Rheumatology (Oxford). 2011;50 (1):161–5. DOI: http://dx.doi.org/10.1093/rheumatology/keq321. Институт ревматологии указан в списке участников работы.

8. Каратеев АЕ, Мовсисян ММ, Ананьева ЛП, Раденска-Лоповок СГ. Патология пищевода при системной склеродермии: данные клинико-эндоскопического обследования. Научно-практическая ревматология. 2012;50(1):54–9. [Karateev AE, Movsisyan MM, Anan'eva LP, Radenska-Lopovok SG. Esophageal pathology in scleroderma systematica: clinical and endoscopic findings. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(1):54–9. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-505.

9. Каратеев АЕ, Мовсисян МС, Раденска-Лоповок СГ, Ананьева ЛП. Реальная частота эрозивного эзофагита и пищевода Барретта при системной склеродермии: данные 12-месячного проспективного исследования. Научно-практическая ревматология. 2012;54(5):51–5. [Karateev AE, Movsisyan MS, Radenska-Lopovok SG, Anan’eva LP. The real prevalence of erosive esophagitis and Barrett's esophagus in systemic scleroderma: data from 12-months prospective study. Nauchno- rakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;54(5):51–5. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2012-1182.

10. Wipff J, Coriat R, Masciocchi M, et al. (в соавт. Л.П. Ананьева). Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow- up study. Rheumatology (Oxford). 2011;50(8):1440–4. DOI: http://dx.doi.org/10.1093/rheumatology/ker110.

11. Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis. 2010;69(1):218–21. DOI: http://dx.doi.org/10.1136/ard.2008.103382. Институт ревматологии указан в списке участников работы.

12. Minier T, Guiducci S, Bellando-Randone S, et al. Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis. 2013;73(12):2087–93. DOI: 10.1136/annrheumdis-2013-203716. Epub 2013 Aug 12. Институт ревматологии указан в списке участников работы.

13. Heijnen IA, Foocharoen C, Bannert B, et al. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol. 2013;31(2 Suppl 76):96–102. Институт ревматологии указан в списке участников работы. 14. Cappelli S, Randone SB, Martinovic D, et al. (в соавт. Л.П. Ананьева, О.А. Конева). Mixed Connective Tissue Disease (MCTD): one diagnosis, more evolutions. 13th Mediterranian Congress on Rheumatology. Croatia, Cavtat; 18–20. 2009 [OP23]

14. Cappelli S, Bellando Randone S, Martinovic D, et al. (в соавт. Л.П. Ананьева, О.А. Конева). «To be or not to be», ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum. 2012;41(4):589–98. DOI: http://dx.doi.org/10.1016/j.semarthrit.2011.07.010.

15. Busch N, Maurer B, Akhmetshina A, et al. (в соавт. Т.А. Невская). The transcription factor fos-related antigen-2 (Fra-2) regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum. 2010;62(1):280–90. DOI: http://dx.doi.org/10.1002/art.25056.

16. Allanore Y, Borderie D, Airo P, et al. (в соавт. Т.А. Невская). Lack of association between 3 vascular endothelial growth factor gene polymorphism and systemic sclerosis: results from multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis. 2007;66(2):257–9. DOI: http://dx.doi.org/10.1136/ard.2006.054346.